BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20087557)

  • 1. PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation.
    Noraini AR; Gay E; Ferrara C; Ravelli E; Mancini V; Morra E; Muti P; Tahir A; Abdul Jalil N; Rossetti C
    Singapore Med J; 2009 Dec; 50(12):1189-95. PubMed ID: 20087557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder.
    Panagiotidis E; Quigley AM; Pencharz D; Ardeshna K; Syed R; Sajjan R; Bomanji J
    Leuk Lymphoma; 2014 Mar; 55(3):515-9. PubMed ID: 23772644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
    Zimmermann H; Denecke T; Dreyling MH; Franzius C; Reinke P; Subklewe M; Amthauer H; Kneba M; Riess H; Trappe RU
    Transplantation; 2018 May; 102(5):868-875. PubMed ID: 29189632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder.
    Guerra-García P; Hirsch S; Levine DS; Taj MM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?
    Nakamoto Y; Nogami M; Sugihara R; Sugimura K; Senda M; Togashi K
    Ann Nucl Med; 2011 Feb; 25(2):93-9. PubMed ID: 20957527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders.
    Blaes AH; Cioc AM; Froelich JW; Peterson BA; Dunitz JM
    Clin Transplant; 2009; 23(6):794-9. PubMed ID: 20447185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison between conventional imaging methods and positron emission tomography in the treatment of Hodgkin's lymphoma].
    Móciková H; Marková J; Bĕlohlávek O; Cáp F; Cermák F; Feltl D; Kozák T
    Cas Lek Cesk; 2004; 143(7):476-9; discussion 479-80. PubMed ID: 15373291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and management roles of FDG PET/CT imaging in post-transplant lympho-proliferation in pediatric heart transplantation.
    Brown AK; Carapellucci J; Oshrine B; Gomez A; Meoded A; Asante-Korang A
    Clin Transplant; 2023 Sep; 37(9):e15015. PubMed ID: 37237443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
    Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
    J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
    Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
    AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
    Montes de Jesus FM; Kwee TC; Nijland M; Kahle XU; Huls G; Dierckx RAJO; van Meerten T; Gheysens O; Dierickx D; Vergote V; Noordzij W; Glaudemans AWJM
    Crit Rev Oncol Hematol; 2018 Dec; 132():27-38. PubMed ID: 30447925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
    Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
    Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.